Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Samuele Butera

SAMUELE BUTERA

GLOBAL COMMERCIAL STRATEGY LEADER

Samuele Butera is the Global Commercial Strategy Leader for Infectious Diseases and Vaccines. He leads Janssen’s efforts to build and maximize the value of the infectious diseases portfolio and pipeline in areas of high unmet need such as HIV, hepatitis B, respiratory syncytial virus (RSV), influenza, and extraintestinal pathogenic E. coli (ExPEC).

With a proven track record in delivering global healthcare innovation and business leadership, Samuele’s goal is to bring transformational solutions to patients, healthcare providers and healthcare systems around the world.

Prior to joining the Johnson & Johnson Family of Companies, Samuele spent 13 years at Novartis, where he was most recently the Global Cell & Gene Therapies Business Leader in Oncology. In this role, he was responsible for leading and overseeing all of Novartis’ activities to ensure the successful global launch of cell and gene therapies, which included the first CAR-T therapy for children and young adults with B-cell acute lymphoblastic leukemia. He also oversaw the market preparations for the launch of the first U.S. biosimilar while leading Sandoz Biopharmaceuticals, North America.

Samuele was formerly a consultant at McKinsey & Company, where he advised clients on corporate strategy, mergers and acquisitions, alliances, operational effectiveness, and organizational redesign. He has also worked in financial markets with Goldman Sachs, and on international economic development initiatives with the United Nations.

Samuele earned a Bachelor of Science in International Economics from Bocconi University in Milan, Italy, and a Master of Public Policy from Harvard University in Boston, Massachusetts.